Compare Ford Motor Company (F) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Gilead Sciences, Inc. — how do they compare? Ford Motor Company trades at $12.28 (market cap $48.85B), while Gilead Sciences, Inc. trades at $147 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 3.7× Ford Motor Company's market cap, and Ford Motor Company pays the higher dividend (4.9%). Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and Gilead Sciences, Inc. for 111 Days on average.
| F | GILD | |
|---|---|---|
Market Cap | $48.85B | $182.40B |
Volume | 57,748,965 | 4,469,821 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $155.80 |
52-Week Low | $11.21 | $116.74 |
Typical Hold Time | 104 Days | 111 Days |
Enterprise Value | $180.81B | $205.46B |
Dividend Yield | 4.9% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.125, down 1.22% with a bearish technical outlook. The company reported mixed quarterly results, beating Q1 and Q2 2026 EPS estimates but missing Q4 2025. Recent news highlights a 6.6% Q3 sales decline due to model phase-outs and supplier issues affecting F-150 production. Cash flow improved in 2025 with $560M net inflow, but profitability remains challenged with negative net income margin of -3.93% and ROE of -18.31%.
Ford faces headwinds from declining sales and profitability challenges, though analyst consensus remains cautiously optimistic with a $15.90 price target. The stock offers value with low P/S (0.26) and P/E (11.21) ratios, but investors must weigh competitive pressures and execution risks against potential turnaround opportunities in hybrid vehicle adoption and commercial divisions.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
